TAD011

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTAD011
Drug Alias NameTAD011单抗注射液TAD011单克隆注射液TAD-011
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumoursBrain NeoplasmsHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesTot Biopharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTot Biopharm Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursBrain NeoplasmsHead and Neck Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A